Cita APA (7a ed.)

HM, C., PY, C., CH, C., & HC, T. (2021). Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Dove Medical Press.

Cita Chicago Style (17a ed.)

HM, Chang, Chou PY, Chou CH, y Tsai HC. Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Dove Medical Press, 2021.

Cita MLA (8a ed.)

HM, Chang, et al. Outcomes After Switching to BIC/FTC/TAF in Patients with Virological Failure to Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors: A Real-World Cohort Study. Dove Medical Press, 2021.